Phase 2 N=114 A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
Hypertension
Primary: Change From Baseline in Ascending Aorta Distensibility at 52 Week — 0.269; 0.330 10^(-3) x mmHg^(-1) — p=0.7324
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Response Rate(CR/CRi) Rate — 6; 9 participants
Phase 2 N=209 A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
Breast Cancer
Primary: Pathological Complete Response (pCR) Rate in Breast After 12 Weeks of Therapy — 24.9; 23.4; 6.9; 9.1 Percentage of Participants
Phase 2 N=14 Lonafarnib for Chronic Hepatitis D
Hepatitis D
Primary: Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy. — -0.13; -0.73; -1.54 log(IU/ml) — p=0.03
Phase 2 N=59 Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) at 6-months — 28 percentage of participants
Phase 2 N=340 Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
Hepatitis C · Chronic Pain
Primary: Percentage of Participants With Rapid Viral Response (RVR) After 4 Weeks of Treatment < the Limit of Quantification (RVR4LOQ) — 28.4; 36.9; 41.9; 84.6 percentage of…
Phase 2 N=517 Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 61; 57; 70; 57 participants
Phase 2 N=15 Beta-hCG + Erythropoietin in Acute Stroke
Acute Stroke
Primary: Safety — 0 participants
Phase 2 N=63 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer
Anal Cancer
Primary: Local Failure Rate at 3 Years — 0.259; 0.353 proportion of participants — p=0.218
Phase 2 N=9 Study of Ruxolitinib in Pancreatic Cancer Patients
Pancreatic Cancer
Primary: Overall Survival — 136.5; 129.5 days — p=0.0494
Phase 2 N=35 A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Malignant Solid Tumor
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Necitumumab — 277; 315 microgram/milliliter (ug/mL)
Phase 2 N=76 Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
HER2 Negative Breast Cancer
Primary: Pathologic Complete Response (pCR) Rate in Patients Treated With ErC for 6 Cycles Prior to Surgery — 18; 10 percentage of surgical patients
Phase 2 N=75 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
Phase 2 N=35 Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery
Congenital Heart Defect · Surgery-Induced Tissue Adhesions · Hemorrhage
Primary: Severity of Adhesions at the Retrosternal Site — 0; 31.3; 0; 37.5 percentage of participants
Phase 2 N=62 A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: Percentage of Participants With Pathological Complete Response — 16 percentage of participants